Cat. #151571
Anti-BRCA2 [MTA42]
Cat. #: 151571
Sub-type: Primary antibody
Unit size: 100 ug
Availability: 10-12 weeks
Target: BRCA2
Class: Polyclonal
Application: ChIP ; IP ; WB
Reactivity: Human ; Mouse
Host: Rabbit
£300.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Madalena Tarsounas
Institute: Cancer Research UK, London Research Institute: Clare Hall Laboratories
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: Anti-BRCA2 [MTA42]
- Alternate name: BRCA 2, BRCA1/BRCA2 containing complex subunit 2, Brca2, BRCA2_HUMAN, BRCC 2, BRCC2, Breast and ovarian cancer susceptibility gene early onset, Breast cancer 2 early onset, Breast Cancer 2 tumor suppressor, Breast cancer susceptibility protein BRCA2, Breast cancer type 2 susceptibility protein, BROVCA2, FACD, FAD 1, FAD, FAD1, FANCB, FANCD 1
- Cancer: Breast cancer;Gynaecologic cancer
- Cancers detailed: Breast cancer;Broadly Applicable;Ovarian
- Research fields: Cancer;Genetics
- Clone: MTA42
- Tool sub type: Primary antibody
- Class: Polyclonal
- Conjugation: Unconjugated
- Molecular weight: 370 kDa
- Reactivity: Human ; Mouse
- Host: Rabbit
- Application: ChIP ; IP ; WB
- Description: Breast Cancer Type 2 susceptibility protein (BRCA2) is a tumour suppressor gene. BRCA2 is involved in the repair of chromosomal damage, specifically in localising Rad51 to double strand breaks. BRCA2 and BRCA1 are frequently mutated in cases of hereditary breast and ovarian cancer.
- Immunogen: Human BRCA2 sequence
- Recommended controls: HeLa and U2OS human cells
Target Details
- Target: BRCA2
- Molecular weight: 370 kDa
- Tissue cell line specificity: HeLa and U2OS human cells
- Target background: Breast Cancer Type 2 susceptibility protein (BRCA2) is a tumour suppressor gene. BRCA2 is involved in the repair of chromosomal damage, specifically in localising Rad51 to double strand breaks. BRCA2 and BRCA1 are frequently mutated in cases of hereditary breast and ovarian cancer.
Applications
- Application: ChIP ; IP ; WB
Handling
- Format: Liquid
- Concentration: 1.47 mg/ml
- Unit size: 100 ug
- Storage buffer: PBS, 0.1% NaN3
- Storage conditions: -15° C to -25° C
- Shipping conditions: Shipping at 4° C
References
- Zhang et al. 2012. Clin Cancer Res. 18(21):5961-71. PMID: 22977194.
- FoxM1 inhibition sensitizes resistant glioblastoma cells to temozolomide by downregulating the expression of DNA-repair gene Rad51.
- Badie et al. 2010. Nat Struct Mol Biol. 17(12):1461-9. PMID: 21076401.
- BRCA2 acts as a RAD51 loader to facilitate telomere replication and capping.
